Abelacimab
Monoclonal antibody
- US DailyMed: Abelacimab
- US FDA: Abelacimab
administration
- Investigational
- 1610943-06-0
- none
- D10821 Y
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of coagulation,[1] under development by Anthos Therapeutics.
Mechanism of action
It is anti-factor XI antibody.[1][2]
See also
- Antibody
- Monoclonal antibody
- Immunology
References
- ^ a b Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, et al. (August 2021). "Abelacimab for Prevention of Venous Thromboembolism". The New England Journal of Medicine. 385 (7): 609–617. doi:10.1056/NEJMoa2105872. PMID 34297496. S2CID 236198598.
- ^ "Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)". Business Wire. 18 September 2023.
- v
- t
- e
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
Glycoprotein IIb/IIIa inhibitors |
|
---|---|
ADP receptor/P2Y12 inhibitors | |
Prostaglandin analogue (PGI2) | |
COX inhibitors | |
Thromboxane inhibitors | |
Phosphodiesterase inhibitors | |
Other |
Vitamin K antagonists (inhibit II, VII, IX, X) | |||||
---|---|---|---|---|---|
Factor Xa inhibitors (with some II inhibition) |
| ||||
Direct thrombin (IIa) inhibitors |
| ||||
Other |
fibrinolytics
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e